{"entity":{"id":"agct1531","kind":"trial","name":"AGCT1531","aka":["COG AGCT1531"],"tldr":"AGCT1531 is testing two ways to spare people with germ cell tumours from long-term harm: watching low-risk patients after surgery and giving chemotherapy only if the tumour returns, and swapping cisplatin for carboplatin, which is kinder to hearing, in standard-risk disease; it is still recruiting.","summary":"AGCT1531 is a Children's Oncology Group phase 3 study run with adult cooperative groups for malignant extracranial germ cell tumours from birth to age 50. Low-risk patients (stage I) enter active surveillance after surgery with chemotherapy reserved for relapse. Standard-risk patients are randomised to bleomycin, etoposide and carboplatin or bleomycin, etoposide and cisplatin, with paediatric and adult dosing schedules; the primary endpoints are event-free and overall survival at two years, and ototoxicity is a central secondary endpoint.\n\nThe registry gives an estimated enrolment of 1,780 with a primary completion date of June 2027 and no results. The corpus's childhood germ cell tumour page cites the AGCT1531 stratum for surveillance with chemotherapy only at relapse.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03067181","url":"https://clinicaltrials.gov/study/NCT03067181"}],"tags":["soc-trials"],"related":[],"cancers":["paediatric-germ-cell-tumours","extragonadal-germ-cell-tumour","testicular","childhood-cancers"],"sections":[],"technologies":["active-surveillance","cytotoxic-chemotherapy"],"targets":[],"drugs":["carboplatin","cisplatin","bleomycin","etoposide"],"companies":[],"institutions":["childrens-oncology-group"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03067181","phase":"3","setting":"Malignant germ cell tumours in children, adolescents and adults up to 50: active surveillance after surgery for low-risk stage I disease, and a randomised comparison of carboplatin against cisplatin with bleomycin and etoposide for standard-risk disease, with hearing loss as a key outcome","sponsor":"Children's Oncology Group","enrolled":1780,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/agct1531/","neighbours":{"cancer":[{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/"},{"id":"extragonadal-germ-cell-tumour","kind":"cancer","name":"Extragonadal germ cell tumour","route":"/cancers/extragonadal-germ-cell-tumour/"},{"id":"paediatric-germ-cell-tumours","kind":"cancer","name":"Germ cell tumours of childhood and adolescence (extracranial and CNS)","route":"/cancers/paediatric-germ-cell-tumours/"},{"id":"testicular","kind":"cancer","name":"Testicular germ cell tumours","route":"/cancers/testicular/"}],"technology":[{"id":"active-surveillance","kind":"technology","name":"Active surveillance","route":"/technologies/active-surveillance/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"bleomycin","kind":"drug","name":"Bleomycin","route":"/drugs/bleomycin/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"}],"institution":[{"id":"childrens-oncology-group","kind":"institution","name":"Children's Oncology Group (COG)","route":"/institutions/childrens-oncology-group/"}]}}